These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 12719859

  • 1. [Development and pre-clinical aspects of pimecrolimus].
    Stütz A, Grassberger M, Meingassner JG.
    Hautarzt; 2003 May; 54(5):405-12. PubMed ID: 12719859
    [Abstract] [Full Text] [Related]

  • 2. Pimecrolimus: a review.
    Gupta AK, Chow M.
    J Eur Acad Dermatol Venereol; 2003 Sep; 17(5):493-503. PubMed ID: 12941081
    [Abstract] [Full Text] [Related]

  • 3. Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus.
    Stuetz A, Baumann K, Grassberger M, Wolff K, Meingassner JG.
    Int Arch Allergy Immunol; 2006 Sep; 141(3):199-212. PubMed ID: 16926539
    [Abstract] [Full Text] [Related]

  • 4. Pimecrolimus (Elidel, SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity.
    Stuetz A, Grassberger M, Meingassner JG.
    Semin Cutan Med Surg; 2001 Dec; 20(4):233-41. PubMed ID: 11770910
    [Abstract] [Full Text] [Related]

  • 5. Pimecrolimus -- an anti-inflammatory drug targeting the skin.
    Grassberger M, Steinhoff M, Schneider D, Luger TA.
    Exp Dermatol; 2004 Dec; 13(12):721-30. PubMed ID: 15560755
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis.
    Breuer K, Werfel T, Kapp A.
    Am J Clin Dermatol; 2005 Dec; 6(2):65-77. PubMed ID: 15799678
    [Abstract] [Full Text] [Related]

  • 7. Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporine A.
    Meingassner JG, Fahrngruber H, Bavandi A.
    J Invest Dermatol; 2003 Jul; 121(1):77-80. PubMed ID: 12839566
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of T-cell activation in vitro in human peripheral blood mononuclear cells by pimecrolimus and glucocorticosteroids and combinations thereof.
    Winiski A, Wang S, Schwendinger B, Stuetz A.
    Exp Dermatol; 2007 Aug; 16(8):699-704. PubMed ID: 17620098
    [Abstract] [Full Text] [Related]

  • 9. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis.
    Hoetzenecker W, Ecker R, Kopp T, Stuetz A, Stingl G, Elbe-Bürger A.
    J Allergy Clin Immunol; 2005 Jun; 115(6):1276-83. PubMed ID: 15940147
    [Abstract] [Full Text] [Related]

  • 10. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis.
    Jensen JM, Scherer A, Wanke C, Bräutigam M, Bongiovanni S, Letzkus M, Staedtler F, Kehren J, Zuehlsdorf M, Schwarz T, Weichenthal M, Fölster-Holst R, Proksch E.
    Allergy; 2012 Mar; 67(3):413-23. PubMed ID: 22142306
    [Abstract] [Full Text] [Related]

  • 11. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
    Hultsch T, Kapp A, Spergel J.
    Dermatology; 2005 Mar; 211(2):174-87. PubMed ID: 16088174
    [Abstract] [Full Text] [Related]

  • 12. Differential inhibition of primary versus preactivated T cells by pimecrolimus but not by tacrolimus in vitro.
    Kalthoff FS, Winiski A, Fichtinger P, Schwendinger B, Wang S, Weishaeupl C, Stuetz A.
    Int Arch Allergy Immunol; 2007 Mar; 142(3):255-64. PubMed ID: 17114891
    [Abstract] [Full Text] [Related]

  • 13. Pimecrolimus for the treatment of inflammatory skin disease.
    Wolff K, Stuetz A.
    Expert Opin Pharmacother; 2004 Mar; 5(3):643-55. PubMed ID: 15013932
    [Abstract] [Full Text] [Related]

  • 14. Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids.
    Kalthoff FS, Chung J, Musser P, Stuetz A.
    Clin Exp Immunol; 2003 Sep; 133(3):350-9. PubMed ID: 12930360
    [Abstract] [Full Text] [Related]

  • 15. Pimecrolimus in dermatology: atopic dermatitis and beyond.
    Gisondi P, Ellis CN, Girolomoni G.
    Int J Clin Pract; 2005 Aug; 59(8):969-74. PubMed ID: 16033622
    [Abstract] [Full Text] [Related]

  • 16. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells.
    Hoetzenecker W, Meingassner JG, Ecker R, Stingl G, Stuetz A, Elbe-Bürger A.
    J Invest Dermatol; 2004 Mar; 122(3):673-84. PubMed ID: 15086553
    [Abstract] [Full Text] [Related]

  • 17. Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis.
    Reitamo S, Remitz A, Kyllönen H, Saarikko J.
    Am J Clin Dermatol; 2002 Mar; 3(6):381-8. PubMed ID: 12113647
    [Abstract] [Full Text] [Related]

  • 18. Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin.
    Ständer S, Ständer H, Seeliger S, Luger TA, Steinhoff M.
    Br J Dermatol; 2007 May; 156(5):1020-6. PubMed ID: 17388925
    [Abstract] [Full Text] [Related]

  • 19. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus.
    Billich A, Aschauer H, Aszódi A, Stuetz A.
    Int J Pharm; 2004 Jan 09; 269(1):29-35. PubMed ID: 14698574
    [Abstract] [Full Text] [Related]

  • 20. [Antipruritic effects of pimecrolimus and tacrolimus].
    Ständer S, Luger TA.
    Hautarzt; 2003 May 09; 54(5):413-7. PubMed ID: 12719860
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.